Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc.
TypePublic
IndustryBiotechnology
Founded1 January 2004 Edit this on Wikidata
HeadquartersPasadena, California,
U.S.
Key peopleChristopher Anzalone, Ph.D., (president and CEO)
RevenueIncrease US$$829.4 million (2025)[1]
Number of employees
609
Websitearrowheadpharma.com

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action.[2][3] The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.[2]

History

In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.[4][5]

In April 2016, the company announced a name change from Arrowhead Research Corporation to Arrowhead Pharmaceuticals, Inc.[6]

In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead's ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.[7]

On October 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. As part of the deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three more RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.[8]

Products

The company has sixteen products in its pipeline, in various stages of development.[2]

ProductIndicationDevelopment phaseNotes
ARO-HBV[2]Hepatitis BIn clinic, phase 2Licensed with Janssen, Phase 2
ARO-AAT[2]Alpha-1 antirypsin deficiencyIn clinic, phase 3Orphan Drug designation, partnered with Takeda
ARO-APOC3[2]HypertriglyceridemiaPhase 2, 3Orphan Drug designation, Fast Track Designation, Phase 3 for FCS, Phase 2 for expanded populations
ARO-HIF2[2]Renal cell carcinomaPreclinical Second generation being worked on presumably
ARO-ENaC[2]Cystic fibrosisPreclinical Second generation being worked on in preclinic
ARO-ANG3[2]DyslipidemiaIn clinic, Phase 2Orphan Drug designation
Olpasiran/ AMG 890[2]Cardiovascular diseaseIn clinic, phase 3Partnered with Amgen
ARO-PNPLA3 NASH In clinic, Phase 1 License returned to ARWR
ARO-HSD NASH In clinic, Phase 1 Licensed to GSK
ARO-C3 Complement Mediated Disease In clinic, Phase 1
ARO-MUC5AC Muco-obstructive In clinic, Phase 1
ARO-RAGE Inflammatory In clinic, Phase 1
ARO-MMP7 Idiopathic Pulmonary Fibrosis In clinic, Phase 1
ARO-COV COVID-19 Preclinical
ARO-DUX4 FSHD Preclinical
HZN-457 Gout In clinic, Phase 1 Partnered with Horizon

References

  1. ↑ "Arrowhead Pharmaceuticals Reports Fiscal 2025 Year End Results". November 25, 2025.
  2. 1 2 3 4 5 6 7 8 9 10 "arwr-10q_20170331.htm". www.sec.gov. Retrieved 2017-05-17.
  3. ↑ "8-K". www.sec.gov. Retrieved 2017-05-17.
  4. ↑ "Arrowhead buys Novartis' RNAi portfolio". Reuters. 2017-03-05. Retrieved 2017-05-17.
  5. ↑ Staff (1 April 2015). "Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10.
  6. ↑ "Arrowhead Research Changes Name to Arrowhead Pharmaceuticals". www.businesswire.com. 2016-04-06. Retrieved 2020-04-06.
  7. ↑ "Amgen, Arrowhead team up on gene-therapies for heart disease". Reuters. 2017-09-29. Retrieved 2017-05-17.
  8. ↑ "Arrowhead Enters $3.7 Billion License and Collaboration". Marketwatch. 2018-10-04. Retrieved 2018-10-04.
  • Official website
  • Business data for Arrowhead Pharmaceuticals, Inc.:
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.